Degenne D - Search Results

1

Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study.

Chaigne B, Gatault P, Darrouzain F, Barbet C, Degenne D, François M, Szymanski P, Rabot N, Golea G, Diot E, Maillot F, Lebranchu Y, Nivet H, Paintaud G, Halimi JM, Guillevin L, Büchler M. Chaigne B, et al. Among authors: degenne d. Clin Exp Immunol. 2014 May;176(2):172-9. doi: 10.1111/cei.12246. Clin Exp Immunol. 2014. PMID: 24304103 Free PMC article. Clinical Trial.

2

An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics.

Ternant D, Cézé N, Lecomte T, Degenne D, Duveau AC, Watier H, Dorval E, Paintaud G. Ternant D, et al. Among authors: degenne d. Ther Drug Monit. 2010 Oct;32(5):647-52. doi: 10.1097/FTD.0b013e3181ef582a. Ther Drug Monit. 2010. PMID: 20720519

3

Abnormalities in CD4+ T lymphocyte subsets in patients with common variable immunodeficiency.

Lebranchu Y, Thibault G, Degenne D, Bardos P. Lebranchu Y, et al. Among authors: degenne d. Clin Immunol Immunopathol. 1991 Oct;61(1):83-92. doi: 10.1016/s0090-1229(06)80009-7. Clin Immunol Immunopathol. 1991. PMID: 1720361

4

Infliximab pharmacokinetics in inflammatory bowel disease patients.

Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G. Ternant D, et al. Among authors: degenne d. Ther Drug Monit. 2008 Aug;30(4):523-9. doi: 10.1097/FTD.0b013e318180e300. Ther Drug Monit. 2008. PMID: 18641542

5

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.

Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H. Gatault P, et al. Among authors: degenne d. MAbs. 2015;7(6):1205-11. doi: 10.1080/19420862.2015.1086049. Epub 2015 Sep 4. MAbs. 2015. PMID: 26337866 Free PMC article.

6

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab.

Cézé N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, Watier H, Lecomte T, Paintaud G. Cézé N, et al. Among authors: degenne d. Ther Drug Monit. 2009 Oct;31(5):597-601. doi: 10.1097/FTD.0b013e3181b33da3. Ther Drug Monit. 2009. PMID: 19730278

7

Evaluation of a peptide ELISA for the detection of rituximab in serum.

Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, Paintaud G, Degenne D, Chatelut E, Cartron G, Le Guellec C. Blasco H, et al. Among authors: degenne d. J Immunol Methods. 2007 Aug 31;325(1-2):127-39. doi: 10.1016/j.jim.2007.06.011. Epub 2007 Jul 17. J Immunol Methods. 2007. PMID: 17651747

8

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.

Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G. Ternant D, et al. Among authors: degenne d. Ther Drug Monit. 2006 Apr;28(2):169-74. doi: 10.1097/01.ftd.0000189901.08684.4b. Ther Drug Monit. 2006. PMID: 16628126 Clinical Trial.

9

Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?

Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot JL, Lemarié E. Diot E, et al. Among authors: degenne d. Chest. 1999 Sep;116(3):715-20. doi: 10.1378/chest.116.3.715. Chest. 1999. PMID: 10492277

10

Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study.

Magnant J, Ohresser M, Allanore Y, de Monte M, Lafosse-Marin M, Degenne D, Guilmot JL, Watier H, Diot E. Magnant J, et al. Among authors: degenne d. Rheumatol Int. 2012 Jul;32(7):2203-7. doi: 10.1007/s00296-011-2026-4. Epub 2011 Jul 23. Rheumatol Int. 2012. PMID: 21785957

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters